Nasal Application of Neuropeptide S Inhibits Arthritis Pain-Related Behaviors through an Action in the Amygdala by Georgina Medina et al.
MOLECULAR PAIN
Medina et al. Molecular Pain 2014, 10:32
http://www.molecularpain.com/content/10/1/32RESEARCH Open AccessNasal application of neuropeptide S inhibits
arthritis pain-related behaviors through an action
in the amygdala
Georgina Medina, Guangchen Ji, Stéphanie Grégoire and Volker Neugebauer*Abstract
Recently discovered neuropeptide S (NPS) has anxiolytic and pain-inhibiting effects in rodents. We showed
previously that NPS increases synaptic inhibition of amygdala output to inhibit pain behaviors. The amygdala
plays a key role in emotional-affective aspects of pain. Of clinical significance is that NPS can be applied nasally to
exert anxiolytic effects in rodents. This study tested the novel hypothesis that nasal application of NPS can inhibit
pain-related behaviors in an arthritis model through NPS receptors (NPSR) in the amygdala. Behaviors and
electrophysiological activity of amygdala neurons were measured in adult male Sprague Dawley rats. Nasal
application of NPS, but not saline, inhibited audible and ultrasonic vocalizations and had anxiolytic-like effects in
the elevated plus-maze test in arthritic rats (kaolin/carrageenan knee joint arthritis model) but had no effect in
normal rats. Stereotaxic application of a selective non-peptide NPSR antagonist (SHA68) into the amygdala by
microdialysis reversed the inhibitory effects of NPS. NPS had no effect on hindlimb withdrawal thresholds. We
showed previously that intra-amygdala application of an NPSR antagonist alone had no effect. Nasal application
of NPS or stereotaxic application of NPS into the amygdala by microdialysis inhibited background and evoked
activity of amygdala neurons in arthritic, but not normal, anesthetized rats. The inhibitory effect was blocked by a
selective NPSR antagonist ([D-Cys(tBu)5]NPS). In conclusion, nasal application of NPS can inhibit emotional-affective,
but not sensory, pain-related behaviors through an action in the amygdala. The beneficial effects of non-invasive NPS
application may suggest translational potential.
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Pain is a multidimensional experience with sensory-
discriminative, emotional-affective and cognitive aspects
[1,2]. Clinical and pre-clinical work now recognizes the
amygdala as an important neural substrate for the
emotional-affective dimension of pain [3-6]. In animals,
activity in the amygdala has been shown to correlate
positively with pain behaviors, and interventions that de-
activate the amygdala have inhibitory effects in different
pain models [4,6-12]. In humans, increased amygdala ac-
tivity has been found in experimental and clinical pain
conditions [5,13-16]. The amygdala circuitry that con-
tributes to the emotional-affective component of pain is
centered on the lateral-basolateral (LA-BLA) and central* Correspondence: volker.neugebauer@ttuhsc.edu
Department of Neuroscience and Cell Biology, University of Texas Medical
Branch at Galveston, 301 Univ. Blvd. RT1069, Galveston, TX 77555-1069, USA
© 2014 Medina et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.(CeA) nuclei [3,4]. The CeA serves output functions
whereas the LA-BLA network provides highly processed
nociceptive and affected-related information to the CeA.
Interposed between LA-BLA and CeA is a cluster of
GABAergic intercalated cells (ITC). These dorsomedial
ITC cells serve as a feedforward inhibitory gate to con-
trol amygdala output from the CeA, which is currently
considered a key mechanism of behavioral extinction of
negative emotions such as fear [17-22].
Importantly, there is evidence to suggest that neuropep-
tide S (NPS), a newly discovered 20 amino-acid peptide,
selectively enhances dorsomedial ITC-dependent feed-
forward inhibition of CeA neurons to produce powerful
anxiolytic effects [23]. NPS binds with high affinity to a
Gq/Gs-coupled receptor (NPSR) to increase intracellular
calcium and cAMP-PKA signaling [24,25]. NPSR mRNA
is expressed in discrete brain areas including the ratLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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the ITC but not LA, BLA and CeA [26] although NPSR
protein appears to be absent in these areas under normal
conditions [27]. We hypothesized that targeting ITC
amygdala cells would also be a useful strategy to control
pain-related amygdala activity and emotional-affective as-
pects of pain behaviors. Recent work from our group
showed decreased feedforward inhibition of laterocapsular
CeA neurons in an arthritis pain model [28,29]. Therefore,
restoring inhibition of the CeA with NPS could be a useful
pharmacological strategy.
Intracerebroventricular administration of NPS was
shown to inhibit aversive and anxiety-like behaviors
[23,30,31] and these effects were mimicked by injections
of NPS directly into the amygdala [32,33]. Intracerebro-
ventricular administration of NPS also had antinociceptive
effects in the tail-flick, hot-pate and formalin tests [34,35],
and we showed recently that direct application of NPS
into the ITC inhibited emotional-affective responses in an
arthritis pain model [29]. Importantly, recent evidence
suggests that NPS can be administered nasally to exert
anxiolytic effects [36,37]. The goal of the present study
was to examine behavioral effects of NPS administered
using a non-invasive (nasal) method; determine the con-
tribution of NPSR in the ITC area of the amygdala to the
effects of nasally applied NPS; and show inhibitory effects
of NPS administered nasally or directly into the ITC on
the activity of CeA output neurons. The results show that
nasally applied NPS can inhibit emotional-affective behav-
iors in an arthritis pain model through an action in the
amygdala without affecting sensory or baseline responses.
Results
In the behavioral experiments, audible and ultrasonic vo-
calizations, anxiety-like behavior and spinal reflexes (hind-
limb withdrawal thresholds) were measured in adult male
Sprague Dawley rats with (n = 29 rats) or without (n = 12
rats) a kaolin/carrageenan-induced arthritis as described in
Methods (Experimental Protocol). Electrophysiological re-
cordings of amygdala neurons were also performed in adult
male Sprague Dawley rats with (n = 20 rats) or without
(n = 5 rats) arthritis (kaolin/carrageenan model). Normal
animals without arthritis served as a control group. These
animals did not receive any needle insertion or vehicle in-
jection to avoid any latent confounding effect of injury
and/or increased intraarticular pressure. Intraarticular sa-
line injection causes a temporary swelling of the joint [38],
which is one of the cardinal symptoms of an inflammation.
Inhibitory effect of nasal NPS on vocalizations of arthritic
rats
Audible vocalizations
Audible vocalizations evoked by brief (15 s) mechanical
compression of the knee with innocuous (300 g/30 mm2)and noxious (1200 g/30 mm2) intensities were measured
in normal (Figure 1A and C) and arthritic rats (Figure 1B
and D). NPS or saline were applied topically onto the rhi-
narium (10 μl on each side) as described in the literature
[36]. In normal rats, nasal application of NPS (14 nmol;
n = 6 rats) or saline (0.9% NaCl; n = 6) had no effect on
the duration of audible vocalizations. Arthritic rats (one
day postinduction) showed an increase in audible vocali-
zations to innocuous (Figure 1B) and noxious (Figure 1D)
stimuli compared to normal rats in agreement with our
previous studies [for review see [39]]. Nasal application of
NPS (14 nmol; n = 8 rats), but not saline (n = 9), in arth-
ritic rats significantly inhibited audible vocalizations to in-
nocuous and noxious stimuli (P < 0.01 and P < 0.05,
respectively; unpaired t-test). The data suggest that nasal
application of NPS can inhibit audible vocalizations in the
arthritis pain model.
Ultrasonic vocalizations
Ultrasonic vocalizations were evoked by brief (15 s) mech-
anical stimuli of innocuous (300 g/30 mm2) and noxious
(1200 g/30 mm2) intensities in normal (Figure 2A and C)
and arthritic rats (Figure 2B and D). In normal rats,
nasal application of NPS (14 nmol; n = 6 rats) or saline
(0.9% NaCl; n = 6) had no effect on the duration of ultra-
sonic vocalizations. Arthritic rats (one day postinduction)
showed increased ultrasonic vocalizations to innocuous
(Figure 2B) and noxious (Figure 2D) stimuli compared to
normal rats. Nasal application of NPS (14 nmol; n = 8
rats), but not saline (n = 9), in arthritic rats significantly
inhibited vocalizations to innocuous and noxious stimuli
(P < 0.01, unpaired t-test). The data suggest that nasal ap-
plication of NPS can inhibit ultrasonic vocalizations of
arthritic rats.
Inhibitory effect of nasal NPS on vocalizations is reversed
by an NPS receptor antagonist in the amygdala
To test the hypothesis that the inhibitory effects of nasal
NPS on vocalizations involve NPS receptors in the
amygdala a selective NPS receptor antagonist (SHA68,
50 μM, concentration in microdialysis probe, 20 min;
n = 6 rats) or ACSF (n = 6 rats) was administered into
the ITC area of the amygdala 25 min after nasal applica-
tion of NPS. These experiments were performed in arth-
ritic rats 4 days postinduction. Audible (Figure 3A and B)
and ultrasonic (Figure 3C and D) vocalizations of arthritic
rats were significantly increased in the presence of the
antagonist compared to ACSF (P < 0.05-0.01, unpaired
t-test), suggesting that the inhibitory effect of NPS (ACSF
group) was blocked by the stereotaxic application of the
antagonist in the amygdala. Therefore, nasal application of
NPS inhibits audible and ultrasonic vocalizations by acti-
vating NPS receptors in the amygdala. The results also
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Figure 1 NPS effects on audible vocalizations. Audible vocalizations were evoked by brief (15 s) innocuous (300 g/30 mm2, A, B) and noxious
(1200 g/30 mm2, C, D) stimulation of the knee joint in normal and arthritic rats. Duration of vocalizations during a 1 min period was measured
before (Pre) and 45 min after nasal application of saline (Sal; n = 6 normal rats; n = 9 arthritis rats) or before (Pre) and 45 min after NPS (14 nmol;
n = 6 normal rats; n = 8 arthritic rats). NPS had significant inhibitory effects in the arthritic pain model. *,** P < 0.05, 0.01, unpaired t-test.
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subacute stage (day 4, Figure 3).
Inhibitory effects of nasal NPS on anxiety-like behavior,
but not locomotion, of arthritic rats
Open-arm preference during the first 5 min in the ele-
vated plus maze (EPM) was measured as an indicator of
anxiety-like behavior in normal (Figure 4A) and arthritic
rats (Figure 4B). Preference for the open arms was lower
in arthritic rats (n = 6) than in normal rats (n = 6) as in
our previous studies [29,39,40], suggesting an increase in
anxiety-like behavior in the pain state. Nasal application
of NPS (14 nmol) had no effect in normal rats (n = 6)
but increased the open-arm choice of arthritic rats sig-
nificantly (n = 6, P < 0.05, unpaired t-test, compared to
rats treated with nasal saline, n = 6). To determine any
effects of NPS on locomotor activity, the total number
of beam crossing into the open and closed arms of
the EPM was measured for 15 min (Figure 4C and D).
Arthritic rats showed a lower number of beam crossings
than normal rats, but nasal application of NPS had nosignificant effect on locomotor activity in normal and in
arthritic rats (P > 0.05, unpaired t-tests). The data sug-
gest that NPS can inhibit pain-related anxiety-like be-
havior without affecting locomotion.
Lack of effect of nasal NPS on spinal reflexes
Hindlimb withdrawal thresholds were measured using
mechanical compression of the knee joint with a cali-
brated forceps in normal (n = 6) and arthritic rats (n = 7)
before and 45 min after a nasal application of saline or
NPS (Figure 5). Mechanical thresholds in arthritic rats
were lower than those in normal rats, but NPS had no
significant effect (P > 0.05, paired t-test comparing pre-
drug and drug values).
Inhibitory effect of NPS on amygdala neurons in arthritic
rats
To show directly that NPS in the amygdala inhibits
pain-related neuronal activity we recorded neurons in
the latero-capsular CeA, which is the output nucleus for
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Figure 2 NPS effects on ultrasonic vocalizations. Ultrasonic vocalizations were evoked by brief (15 s) innocuous (300 g/30 mm2, A, B) and
noxious (1200 g/30 mm2, C, D) stimulation of the knee joint in normal and arthritic rats. Duration of vocalizations during a 1 min period was
measured before (Pre) and 45 min after nasal application of saline (Sal; n = 6 normal rats; n = 9 arthritic rats) or before (Pre) and 45 min after NPS
(14 nmol; n = 6 normal rats; n = 8 arthritic rats). NPS had significant inhibitory effects in the arthritic pain model. ** P < 0.01, unpaired t-test.
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of animals that were not subjected to the behavioral
tests. While our previous study determined the synaptic
site and mechanism of action of NPS in the amygdala
(ITC-driven inhibition of CeA neurons) [29], the neur-
onal effect of NPS on nociceptive processing in the
amygdala of the intact animal has not yet been ad-
dressed. Here we recorded individual CeA neurons that
responded more strongly to brief noxious than innocu-
ous test stimuli under normal conditions, which are so-
called “multireceptive” neurons according to our classifi-
cation of amygdala neurons [3,4]. Test stimuli (15 s)
were applied to the knee joints as in the behavioral ex-
periments (see Methods).
All neurons (n = 17) were recorded under normal con-
ditions; of these, 12 were also recorded continuously
during the development of a subsequently induced knee
joint arthritis (kaolin/carrageenan model, see Methods).
Only one neuron was recorded in each rat. NPS was ad-
ministered nasally or stereotaxically into the area of theITC, which is lateral to the CeA. Our previous brain
slice studies showed that NPS increased ITC-mediated
synaptic inhibition of CeA neurons without acting directly
on CeA or BLA neurons [29]. Based on pharmacological
data from these experiment, drugs were administered by
microdialysis for 20 min at a concentration 100 times that
of the desired tissue concentration. Measurements of
neuronal activity were made 15 min after the start of drug
application.
Figure 6 shows individual examples. Data are summa-
rized in Figure 7. NPS (100 μM, concentration in microdi-
alysis probe) had no effect on background or evoked
activity of CeA neurons (n = 5) in normal animals without
arthritis (Figures 6A and 7A). In the arthritis pain model
(6-8 h postinduction), NPS significantly inhibited back-
ground and evoked activity (n = 12 neurons; P < 0.05-
0.001, Newman-Keuls posttests; Figures 6B and 7B).
Coapplication of a selective NPSR antagonist ([D-Cys
(tBu)5]NPS; 1 mM, concentration in the microdialysis
























































Figure 3 NPSR antagonist blocks NPS effects on vocalizations.
Audible (A) and ultrasonic (B) vocalizations were evoked by brief
(15 s) innocuous (300 g/30 mm2, A, C) and noxious (1200 g/30 mm2,
B, D) stimulation of the knee joint in arthritic rats (4 days postinudction).
Duration of vocalizations during a 1 min period was measured during
stereotaxic application of an NPS receptor antagonist (SHA68, 50 μM,
concentration in microdialysis probe, 20 min; n = 6 rats) or ACSF
(vehicle control; n = 6 rats) following nasal application of NPS.
Stereotaxic applications started 25 min after NPS and behavioral
measurements were made 45 min after NPS. Compared to NPS
coapplied with ACSF, vocalizations were significantly increased
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Figure 4 NPS effects on anxiety-like behavior but not locomotor
activity. (A, B) Open-arm choice during the initial 5 min in the
elevated plus-maze (see Methods) was measured in normal (A)
and arthritic rats (B) 30 min after nasal application of saline (Sal;
n = 6 normal rats; n = 6 arthritic rats) or NPS (14 nmol; n = 6 normal
rats; n = 6 arthritic rats). NPS increased open-arm choice in arthritic
animals significantly. * P < 0.05, unpaired t-test. (C, D) Locomotor
activity was measured in the same groups of normal (C) and
arthritic (D) rats as the total number of beam crossing into the 4
arms during 15 min. NPS had no significant effect (unpaired t-test).
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and 7B). In another sample of CeA neurons recorded in
arthritic rats, nasal application of NPS (14 nmol) also inhib-
ited CeA activity significantly (n = 6 neurons; P < 0.001,
Newman-Keuls posttests, Figure 7C) and this effect was
reversed by a selective NPSR antagonist (SHA68, 50 μM,
concentration in microdialysis probe, 20 min) applied
stereotaxically into the ITC area (n = 6 neurons; P < 0.01-
0.001, Newman-Keuls posttests). The results show that
NPS acts on NPSR in the ITC area to inhibit nociceptive
processing of CeA neurons in a pain state but not under
normal conditions.Discussion
The key novelty of this is study is the finding that nasal
application of recently discovered neuropeptide S (NPS)
can inhibit pain behaviors in an arthritis model. This effect
involves NPS receptors in the amygdala, specifically the
intercalated cell (ITC) area that serves as a gate keeper of
excitatory drives to amygdala output neurons in the CeA.
Moreover, new electrophysiology results show that NPS
administered nasally or directly into the ITC area inhibits
nociceptive processing in CeA neurons that are known to
play an important role in the generation and modulation
of pain behaviors [3,4]. While our previous work identified
ITC-driven inhibition of CeA neurons as the synaptic























Figure 5 Lack of NPS effects on hindlimb withdrawal thresholds. Using calibrated forceps for mechanical compression of the knee joint,
reflex thresholds were measured in normal (A) and arthritic rats (B) before (Pre) and 45 min after a nasal application of saline (Sal; n = 6 normal
rats; n = 7 arthritic rats) or before (Pre) and 45 min after NPS (14 nmol; n = 6 normal rats; n = 7 arthritic rats). NPS had no significant effect
(one-way ANOVA).
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rons in the intact animal was not known. The behavioral
and electrophysiological results are significant because the
beneficial effects obtained with a non-invasive application
method may suggest potential usefulness in the clinical
setting, although NPS functions in humans remain to
be determined. However, human NPS and NPS recep-
tors exist and the primary sequence of NPS is highly
conserved among vertebrates especially at the N-terminus
with the amino acid serine (S) hence the name neuropep-
tide S [24,25,31].
NPS is primarily localized to discrete brainstem areas,
including the lateral parabrachial nucleus and the peri-
locus coeruleus [27]. These brainstem areas interact
closely with the amygdala, for example through cortico-
tropin releasing factor (CRF) expressing neurons in the
lateral parabrachial nucleus and in the amygdala (CeA)
[41-44]. CRF can activate NPS neurons in the locus
coeruleus [45]. The amygdala CRF system plays an im-
portant role in pain modulation and generation of pain
behaviors [6,46,47]. The amygdala is also one of the
brain areas where NPSR is found in highest abundance
[26]. NPS has been shown to control amygdala output
by increasing synaptic feedforward inhibition mediated
by a cluster of inhibitory ITC interneurons as a mechan-
ism to exert anxiolytic effects [23]. Recent work from
our group suggests that a similar mechanism may also
account for pain-inhibiting effects of NPS [29]. Thus,
NPS could be part of a homeostatic circuit of emotions
involving limbic and brainstem areas [48].
In support of this notion, behavioral studies showed
anxiolytic effects of NPS in the brain. Intracerebroven-
tricular administration of NPS had anxiolytic effects in
various assays and facilitated the extinction of condi-
tioned fear responses [23,30,31,36,49]. Administration of
an NPS receptor antagonist (SHA68) into the amygdalareversed the effects of NPS, suggesting a major role of
the amygdala in NPS function. Intracerebroventricular
administration of NPS also had antinociceptive effects in
the tail-flick, hot-pate and formalin tests [34,35]. We
showed previously that direct application of NPS into
the ITC of the amygdala inhibited emotional-affective
responses and anxiety-like behavior in an arthritis pain
model but had no effect on sensory aspects (mechanical
withdrawal thresholds) [29], suggesting the involvement
of NPS in the amygdala in discrete aspects of pain
modulation. The results of the present study provide fur-
ther support of this concept.
Importantly, recent evidence suggests that NPS can be
administered nasally to exert anxiolytic effects [36,37].
Topical application of NPS on the rhinarium (glabrous
area around the nostrils) of rats increased novel object
recognition, a common method for assessing cognitive
memory enhancing effects, and had anxiolytic effects in
the elevated plus-maze [36]. A study in mice reported
that application of NPS to each nostril had anxiolytic ef-
fects on the elevated plus-maze and dark-light tests [37].
Locomotor activity was not affected in these studies. To
the best of our knowledge, the present study is the first
to examine the effects of nasal NPS on pain behaviors
and amygdala activity. We also show that inhibitory ef-
fects of NPS in the pain model are mediated through
NPS receptors in the amygdala, because stereotaxic ap-
plication of a selective NPSR antagonist reversed the ef-
fects of NPS. Importantly, NPS had no effect under
normal conditions, which is consistent with our previous
study using stereotaxic application of NPS into the
amygdala [29]. We interpret our data as evidence for a
compensatory change in NPSR function and/or expres-
sion, which would be consistent with homeostatic func-
tions of the NPS amygdala system. Although high levels






















































Figure 6 NPS effects on individual amygdala neurons. Extracellular single unit recordings of individual amygdala neurons in the central
nucleus (CeA). Oscilloscope traces show original recordings of action potentials (spikes). Peristimulus rate histograms show spikes/s; bin width 1 s.
Horizontal lines indicate innocuous and noxious test stimuli (compression of the knee joint; see Methods). (A) Stereotaxic administration of NPS
(100 μM, concentration in microdialysis probe; 20 min) into the ITC area did not change the activity of a CeA neuron in a normal rat. (B) Stereotaxic
administration of NPS into the ITC inhibited the activity of another CeA neuron in a rat with arthritis (6 h postinduction). (C) Coapplication of a
selective NPSR antagonist ([D-Cys(tBu)5]NPS, 1 mM, concentration in microdialysis probe; 20 min) into the ITC area blocked the effect of NPS in another
CeA neuron recorded in an arthritic rat (6 h postinduction).
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under normal conditions [27]. NPSR protein expression
in the arthritis pain model remains to be determined.
Some methodological aspects need to be considered.
We selected the 45 min time point after nasal NPS for the
following reasons: Previous studies detected behavioraleffects 30 min after nasal NPS [36,37]. Internalization
of the NPS receptor-ligand complex in the brain, includ-
ing the amygdala, was detected 30 min after nasal applica-
tion of fluorophore-conjugated NPS [37]. In our preliminary
pilot experiments, behavioral effects of nasal NPS were



































Figure 7 NPS effects in the sample of amygdala neurons.
Summary of data for the sample of CeA neurons tested in normal
rats (n = 5 neurons; A) and in arthritic rats (6-8 h postinduction;
n = 20 neurons, B and C). Bar histograms show average spikes/s
(mean ± SE) as percent of predrug control values (set to 100%).
Statistical analysis was performed on raw data. Background activity
was measured as average firing rate over 3-5 min. For evoked “net”
responses, background activity (15 s) was subtracted from the total
activity during stimulation (15 s). (A) Stereotaxic application of NPS
(100 μM, concentration in microdialysis probe; 20 min) into the ITC
area had no effect under normal conditions. (B) NPS in the ITC
inhibited background and evoked activity in arthritic rats significantly
(n = 12 neurons; *,**,*** P < 0.05-0.001, Newman-Keuls posttests
compared to predrug). Coapplication of a selective NPSR antagonist
([D-Cys(tBu)5]NPS, 1 mM, concentration in microdialysis probe;
20 min) into the ITC area reversed the effect of NPS significantly
(n = 7 neurons; ##,### P < 0.01-0.001, Newman-Keuls posttests
compared to NPS alone). (C) Nasal application of NPS inhibited
background and evoked activity of CeA neurons significantly (n = 8
neurons; *** P < 0.001, Newman-Keuls posttests). Application of a
selective NPSR antagonist (SHA68, 50 μM, concentration in microdialysis
probe, 20 min) reversed the effect of NPS significantly (n = 6
neurons, ### P < 0.001, Newman-Keuls posttests).
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It should be noted that a previous study showed that NPS
(total of 20 μl) was completely absorbed within 2 min after
topical nasal application.
The dose of 14 nmol NPS was selected based on data
in the literature. In rats, nasal application of NPS
(4 nmol) was effective on object discrimination (mem-
ory-enhancing effect) whereas anxiolytic effects were de-
tected with NPS (40 nmol) but not NPS (4 nmol) [36]. A
study in mice tested intranasal NPS (7, 14 and 28 nmol)
and found that NPS (14 nmol) was the optimum dose
for anxiolytic effects [37]. We considered, but did not
perform, a dose-response analysis because it would have
significantly increased the number of animals without
changing the key finding of this study, which is the
beneficial effect of nasal NPS through an action on
NPSR in the amygdala. Still, we acknowledge this as a
potential shortcoming of our study.
Drug concentrations for stereotaxic application by mi-
crodialysis were derived from data in the literature and
our own work [29]. In brain slices from arthritic rats,
NPS (1 μM) inhibited synaptic plasticity in CeA neurons
significantly through a direct action on ITC cells. In
mice brain slices, NPS (10 μM) had near maximum ef-
fects on synaptic activation of ITC cells but the mechan-
ism of action was presynaptic to ITC cells [23]. The
rather indirect synaptic effect and species differences
may explain differences in effective concentrations. Our
previous studies comparing drug effects in brain slices
and microdialysis drug application in intact animals de-
termined that microdialysis required a 100-fold higher
concentration than that needed in the tissue because of
the concentration gradient across the dialysis membrane
Medina et al. Molecular Pain 2014, 10:32 Page 9 of 13
http://www.molecularpain.com/content/10/1/32and diffusion in the tissue [29,40,46,47,50]. Drug con-
centrations for microdialysis application were adjusted
accordingly in the present study. Importantly, NPS ef-
fects were blocked by competitive NPSR antagonists,
confirming the appropriateness of the selected concen-
trations. We showed previously that [D-Cys(tBu)5]NPS,
a well-established selective NPSR antagonist [51], blocked
synaptic effects of NPS in the amygdala slice preparation
(10 μM) and behavioral effects of NPS when applied by
microdialysis (1 mM) into the ITC area [29], and so we
used these concentrations in the present study. SHA68, a
selective non-peptide NPSR antagonist [52,53], has be-
come commercially available only recently. In vitro assays
of calcium mobilization showed that SHA68 (10 nM to
1 μM) antagonized the effects of NPS with IC50 values of
about 50 nM but was inactive per se [49,52]. In radioli-
gand binding experiments a Ki value of about 50 nM was
also found as well [52]. The concentration used in the mi-
crodialysis probe in our studies (50 μM) was based on the
assumption that a submaximal concentration would be
needed to fully antagonize the effects of NPS. This con-
centration is relatively low compared to those used in
other studies where the injection of SHA68 (10 μM) into
the amygdala antagonized behavioral effects of NPS
(10 μM) and SHA68 (100 μM) antagonized the synaptic
effects of NPS in mice [23]. Differences in the mode of ac-
tion of NPS in the amygdala of rats (directly on ITC) and
mice (indirectly, presynaptic to ITC) may explain the
lower concentration needed in our study.
Finally, we did not perform placement control injec-
tions in this study. Drug injections targeted the ITC area
in behavioral and electrophysiological experiments. Our
previous studies on synaptic effects of NPS in brain
slices showed a direct action on ITC cells but not on
CeA or BLA neurons (synaptic inhibition of CeA neu-
rons was driven by NPSR activation on ITC cells) [29].
Accordingly, administration of NPS into the CeA as a
control in our previous behavioral studies had no effect
[29] and therefore we did not repeat these experiments
here. Although NPSR antagonist injection into the ITC
area blocked the effect of nasal NPS completely, we can-
not rule out the contribution of NPSR in other brain
areas. For example NPSR activation by nasal NPS has
been found in the ventral hippocampus [37].
Conclusions
This study provides important new evidence that re-
cently discovered neuropeptide S (NPS) administered
using a noninvasive method (nasal application) can in-
hibit pain-related emotional-affective behaviors through
an action involving the amygdala. Nasal application of
NPS inhibited emotional-affective pain behaviors in an
arthritis model. This effect involved NPS receptors in
the amygdala. NPS administered nasally or directly intothe intercalated cell (ITC) area inhibited nociceptive
processing in CeA neurons that are known to play an
important role in the generation and modulation of
pain behaviors.
Methods
Male Sprague Dawley rats (225-350 g) were housed in a
temperature controlled room and maintained on a
12 h day/night cycle with continuous access to food and
water. On the day of the experiment rats were trans-
ferred from the animal facility and allowed to acclimate
to the laboratory for at least 1 h. After completion of the
experiments, the animals were euthanized through de-
capitation using a guillotine (Harvard Apparatus Decapi-
tator). All experimental procedures conform to the
guidelines of the International Association for the Study
of Pain (IASP) and of the National Institutes of Health
(NIH) and were approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of
Texas Medical Branch (UTMB).
Arthritis pain model
Behavioral and electrophysiological experiments were
carried out in normal and in arthritic rats. An acute
arthritis was induced in the left knee joint as described
before [54]. A kaolin suspension (4%, 80-100 μl) was
injected into the left knee joint cavity. After repetitive
flexion and extensions of the knee for 15 min, a carra-
geenan solution (2%, 80-100 μl) was injected into the
joint cavity, and the leg was flexed and extended for an-
other 5 min. Inflammation and swelling of the knee
occur consistently after 1-3 h of induction, reach a max-
imum plateau at 5-6 hours and persist for several days
[54].
Behavioral tests
Audible and ultrasonic vocalizations to mechanical
stimulation
Animals were briefly anesthetized with isoflurane (2%,
precision vaporizer) and placed in a custom-designed re-
cording chamber for the measurement of vocalizations.
The chamber allowed access to the hind limbs for the
application of mechanical (tissue compression) stimuli.
Animals recovered from anesthesia and were habituated
to the test environment. Audible (20 Hz to 16 Hz) and
ultrasonic (25 ± 4 kHz) vocalizations were measured
using a microphone and bat detector, respectively, which
were placed in front of the animal at a fixed distance.
Experiments were carried out in a shielded room and
appropriate filtering levels were used to avoid the re-
cording of any background noise. Brief (15 s) mechanical
stimuli of innocuous (300 g/30 mm2) and noxious
(1200 g/30 mm2) intensities were applied to the left knee
joint, using a calibrated forceps with a force transducer
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of events of audible and ultrasonic vocalizations were ana-
lyzed using Ultravox 2.0 software (Noldus Information
Technology). Vocalizations were recorded for periods of
1 min starting with the onset of each mechanical stimulus.
Spinal reflexes
Thresholds of hindlimb withdrawal reflexes were mea-
sured after the vocalization tests by applying mechan-
ical stimuli of continuously increasing intensity to the
knee, using a calibrated forceps with force transducer.
The area of tissue compressed by the tip of the forceps
was 30 mm2 and the reflex threshold was expressed as
g/30 mm2.
Elevated plus-maze (EPM)
Anxiety-like behavior was measured in normal and in
arthritic rats treated with nasal NPS or saline (see Experi-
mental protocol). The elevated plus-maze (Columbus In-
struments) was used as described previously [29]. The
EPM has two enclosed and two open arms that are ar-
ranged in a plus shape. The platform was elevated 70 cm
above the floor. The EPM was equipped with photocells
to detect animal movements in the open and closed arms.
Recordings and analyses were made using Multi-Varimex
software (Columbus Instruments). The animal was placed
onto the central area of the plus-maze, facing an open-
arm. Anxiety-like behavior was analyzed as the ratio of
open-arm entries to the total number of entries (expressed
as %) during 5 min. The total number of beam crossings
during 15 min was used as an indicator of locomotor ac-
tivity of the animal.
Experimental protocol
NPS (14 nmol) or saline (0.9% NaCl) was applied nasally
30-45 min prior to testing, because our pilot time-
course data showed that nasally applied NPS had a max-
imum effect on vocalizations (in arthritic rats) between
30-45 min. NPS and saline were tested in normal ani-
mals and in arthritic animals. The protocol for behav-
ioral experiments was as follows. On day 1, arthritis was
induced in the arthritis group; EPM test was performed
in normal animals and in arthritic animals (5-6 hours
postinduction) 30 min after nasal NPS (14 nmol) or sa-
line (0.9% NaCl). On day 2, audible and ultrasonic vocal-
izations were measured in normal and arthritic animals
before and after nasal application of NPS (14 nmol) or
saline (0.9% NaCl). On day 3, a guide cannula was im-
planted in arthritic animals for stereotaxic drug applica-
tion (NPSR antagonist or ACSF control) by microdialysis
into the ITC area of the amygdala (lateral to the central
nucleus; see below). Stereotaxic injections of the antag-
onist or ACSF were done only in arthritic animals be-
cause NPS had no effect in normal animals. On day 4, amicrodialysis probe was inserted through the guide can-
nula and a selective NPS receptor antagonist (SHA68,
50 μM, concentration in microdialysis probe) or ACSF
(vehicle control) was applied stereotaxically into the
amygdala by microdialysis 25 min after nasal application
of NPS (14 nmol) to determine the ability of the antag-
onist to block the effects of NPS. Since NPS had effects
only in arthritic rats, the antagonist was also tested only
in the arthritis group. Vocalizations were measured
20 min after SHA68, i.e., 45 min after NPS.
Electrophysiological recordings of amygdala neurons
Extracellular single-unit recordings were made from CeA
neurons in rats anesthetized with pentobarbital. These an-
imals were not tested in the behavioral experiments.
Animal preparation and anesthesia
Experimental details have been described in detail in our
previous studies [40,55,56]. The animal was anesthetized
with pentobarbital sodium (50 mg/kg, i.p.). Constant
levels of anesthesia were maintained with pentobarbital
administered through a catheter in the jugular vein
(15 mg/kg per h). A cannula was inserted into the tra-
chea for artificial respiration. After paralysis with pan-
curonium (0.3 mg/h, i.v.) the animal was artificially
ventilated (3–3.5 ml; 55–65 strokes/min). End-tidal CO2
levels (kept at 4.0 ± 0.2%), heart rate and electrocardio-
gram (ECG) pattern were continuously monitored. Core
body temperature was maintained at 37°C by means of a
homeothermic blanket system. The animal was mounted
in a stereotaxic frame (David Kopf Instr.) and a small
unilateral craniotomy was performed at the sutura
fronto-parietalis level for the insertion of the recording
electrode and microdialysis probe. Electrophysiological
recording and identification of CeA neurons.
Extracellular single-unit recordings were made with
glass insulated carbon filament electrodes (4 - 6 MΩ) as
described in detail previously [40,55,56], using the follow-
ing stereotaxic coordinates [57]: 2.2-3.1 caudal to bregma,
3.8-4.2 lateral to midline, depth 6.5-8.0. The recorded sig-
nals were amplified, band-pass filtered (300 Hz to 3 kHz),
displayed on an analog oscilloscope, and processed by
an interface (CED 1401 Plus). Spike2 software (CED,
version 4) was used for spike sorting, data storage and
analysis of single-unit activity. Spike size and configur-
ation were continuously monitored. Only those neurons
were included in the study whose spike configuration
matched a preset template and could be clearly discrimi-
nated from activity in the background throughout the
experiment.
Experimental protocol
In each animal, background and evoked activity of only one
neuron were recorded as described in detail previously
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intentional stimulation was recorded for 10 min. Brief
(15 s) mechanical stimuli of innocuous (300 g/30 mm2) and
noxious (1200 g/30 mm2) intensities were applied to the left
knee joint as in the behavioral experiments, using a cali-
brated forceps with a force transducer, whose output signal
was amplified, displayed in grams on an LCD screen,
digitized by the CED interface, and recorded for on-
and offline analysis. For the analysis of net evoked ac-
tivity, background activity in the 15 s time period pre-
ceding the 15 s stimulus was subtracted from the total
activity during stimulation. Neurons were selected which
had a receptive field in the knee joint and responded more
strongly to noxious than innocuous mechanical stimuli.
After characterization of a CeA neuron, NPS was applied
nasally or stereotaxically into the ITC area. In some neu-
rons, the effect of stereotaxic application of a selective
NPSR antagonist into the ITC area was tested. The antag-
onist was either coapplied with stereotaxically administered






















Figure 8 Location of microdialysis probes and recording electrodes in
application of an NPSR antagonist or ACSF into the ITC area of the amygda
tips of microdialysis probes for application of NPSR antagonists into the ITC
(C) Position of the tips of the glass insulated carbon filament electrodes fo
nucleus (CeA); n = 5 normal, n = 20, arthritis. Open circles, data from normaDrugs and drug application
NPS was purchased from Tocris Bioscience. SHA68, a se-
lective non-peptide NPSR antagonist [52,53] was pur-
chased from Bachem. [D-Cys(tBu)5]NPS, a well-established
selective NPSR antagonist, synthesized as described be-
fore [51], was a generous gift from Drs. Remo Guerrini
and Girolamo Calo, University of Ferrara, Italy.
Nasal application
NPS dissolved in saline was applied bilaterally (10 μl
each) onto the glabrous skin area around the nostrils
(rhinarium), but not into the nostrils, using a pipetter as
described by others [36]. The animal was held in a su-
pine position. Solutions are completely absorbed within
2 min [36].
Microdialysis
Rats for the behavioral experiments were anesthetized
with pentobarbital sodium (Nembutal, 50 mg/kg, i.p.) on
day 3 post-induction of arthritis. A guide canula was im-





the amygdala. (A) Positions of the tips of microdialysis probes for
la, lateral to the CeA, in behavioral studies; n = 14. (B) Positions of the
area in electrophysiology experiments; n = 5 normal, n = 18 arthritis.
r extracellular recordings of individual amygdala neurons in the central
l rats; filled circles, data from arthritic rats.
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using the following coordinates [57]: 2.3-3.1 mm caudal
to bregma, 4.5-4.8 mm lateral to midline, 7.2-7.6 mm
depth. Guide cannulas were fastened to the skull with
dental acrylic (Plastic One, Roanke, VA). The following
day, a microdialysis probe (CMA/Microdialysis 11, Solona
Sweden) was inserted through the guide cannula for
stereotaxic drug application into the amygdala. In the
electrophysiology experiments the microdialysis probe
was inserted directly into the amygdala through the crani-
otomy (see previous section). The probe was connected to
an infusion pump (Harvard Apparatus). NPS and NPSR
antagonists were dissolved in artificial cerebral spinal fluid
(ACSF) on the day of the experiment and applied by mi-
crodialysis at a rate of 5 μl/min. ACSF (oxygenated and
equilibrated to pH 7.4) contained the following (in mM):
125.0 NaCl, 2.6 KCl, 2.5 NaH2PO4, 1.3 CaCl2, 0.9 MgCl2,
21.0 NaHCO3, and 3.5 glucose. The position of the micro-
dialysis probes in the amygdala was verified histologically
at the end of the experiment as in our previous studies
[29] (see Figure 8).
Statistical analysis
All averaged values are given as the mean ± standard
error of the mean (SEM). GraphPad Prism 3.0 software
(Graph-Pad, San Diego, CA) was used for all statistical
analyses. Student’s t-test (paired or unpaired when ap-
propriate) was used to compare 2 sets of data. analyses.
Student’s t-test (paired or unpaired when appropriate)
was used to compare 2 sets of data. For multiple com-
parisons (Figure 7), one-way analysis of variance
(ANOVA) was used followed by Newman-Keuls post-
tests where appropriate (see Results). Statistical signifi-
cance was accepted at the level P < 0.05.
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